synthagen laboratories bpc-157 - NL-157 - For Muscle Recovery and Tissue Repair - For Joint and Tendon Support NL-BPC-157 - Body Protection Complex

Retatrutide Research# The pivotal Phase 2 trial (338 participants, NEJM 2023) showed 24.2% weight loss at 48 weeks

P., Parhiz, H., Perera, C

Important safety warnings seek urgent medical attention if you experience: Severe or persistent abdominal pain, which may radiate to the back this could indicate pancreatitis , a serious but rare risk associated with GLP-1based therapies as a class [16] [17] Right upper quadrant pain, fever, or jaundice these may suggest gallbladder disease , another class-associated risk Signs of dehydration (dizziness, reduced urine output, extreme thirst) resulting from severe vomiting or diarrhoea, which can affect kidney function Pregnancy and breastfeeding: Use of GLP-1based therapies and related investigational agents is not recommended during pregnancy or breastfeeding

Qi et al., 2025)